AbbVie Inc. (ABBV) Position Reduced by Stockman Wealth Management Inc

Baltimore Capital Management Inc. lessened its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 49.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). (NYSE:ABBV). First Long Island Limited Liability Company owns 175,434 shares.

AbbVie Inc. has a 52-week low of $58.80 and a 52-week high of $98.52. It increased, as 55 investors sold ABBV shares while 581 reduced holdings. Intercontinental Wealth Advisors LLC acquired a new stake in shares of AbbVie in the second quarter valued at $345,000.

Sell side analysts plays vital role in buying and selling a stock where 3 analysts rated AbbVie Inc. Farr Miller & Washington LLC DC now owns 11,338 shares of the company's stock valued at $822,000 after purchasing an additional 1,032 shares during the period. It also increased its holding in Gentherm Inc (NASDAQ:THRM) by 32,026 shares in the quarter, for a total of 267,933 shares, and has risen its stake in Neogenomics (NASDAQ:NEO). As per Friday, April 28, the company rating was maintained by BMO Capital Markets. Tradewinds Capital Management LLC now owns 2,269 shares of the company's stock worth $148,000 after buying an additional 1,057 shares during the period. Corporate insiders own 0.23% of the company's stock. $77.11's average target is -18.82% below currents $94.9908 stock price. (NYSE:ABBV) opened at $95.41 on Wednesday. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Chairman Richard A. Gonzalez sold 218,193 shares of AbbVie stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $94.01, for a total transaction of $20,512,323.93. Following the transaction, the chairman now owns 492,030 shares of the company's stock, valued at approximately $46,255,740.30. The disclosure for this sale can be found here. Insiders have sold 277,125 shares of company stock worth $25,891,756 over the last three months. Jefferies maintained AbbVie Inc. Flagship Harbor Advisors LLC raised its position in shares of AbbVie by 4.3% during the second quarter. The company has a quick ratio of 1.32, a current ratio of 1.45 and a debt-to-equity ratio of 5.08. (NYSE:ABBV) has "Market Perform" rating given on Thursday, November 16 by BMO Capital Markets. AbbVie Inc. has a 12-month low of $58.80 and a 12-month high of $98.52.

Dos bajas encendieron las alarmas en la práctica de Boca
La práctica de fútbol en espacios reducidos se llevó a cabo a puertas cerradas en la cancha número uno del complejo de Casa Amarilla.

Among 21 analysts covering Abbvie Inc (NYSE:ABBV), 11 have Buy rating, 1 Sell and 9 Hold. Sns Gp Lc holds 1.37% or 71,324 shares in its portfolio. The firm had revenue of $7 billion for the quarter, compared to analyst estimates of $7 billion. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. Farr Miller & Washington LLC DC increased its position in AbbVie by 10.0% during the 2nd quarter. Texas-based Fruth Investment Mngmt has invested 1.26% in AbbVie Inc.

The business also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Investors of record on Friday, January 12th will be given a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 2.98%. This is a boost from AbbVie's previous quarterly dividend of $0.64. AbbVie's dividend payout ratio (DPR) is 62.29%. ABBV has been the subject of several analyst reports. UBS reaffirmed a "neutral" rating on shares of AbbVie in a research note on Friday, October 13th. Barclays Capital maintained the shares of ABBV in report on Friday, October 13 with "Equal-Weight" rating. (NYSE:ABBV). Wellington Shields & Lc holds 19,193 shares. Evercore ISI assumed coverage on AbbVie in a research note on Wednesday, August 16th. On Friday, December 2 the stock rating was maintained by TD Securities with "Buy". Deutsche Bank raised their target price on shares of AbbVie to $88.00 and gave the company a "hold" rating in a research report on Thursday, September 28th. Qualcomm Inc. had 122 analyst reports since July 23, 2015 according to SRatingsIntel. Finally, BidaskClub raised AbbVie from a "buy" rating to a "strong-buy" rating in a research report on Saturday, November 11th. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of USA & global trademark and copyright legislation. The original version of this news story can be read at Envestnet Asset stated it has 0.08% in AbbVie Inc. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Noticias recomendadas

Nos complace brindar esta oportunidad para compartir información, experiencias y observaciones sobre lo que está en las noticias.
Algunos de los comentarios se pueden reimprimir en otras partes del sitio o en el periódico.
Gracias por tomarse el tiempo para ofrecer sus pensamientos.